Skip to main content

Madrigal Pharmaceuticals, Inc Investor Event Transcript, Nov 17, 2026

Madrigal Pharmaceuticals, Inc. (MDGL)

Madrigal Pharmaceuticals said the Maestro Nash outcomes readout is now expected in late 2027 and that it can start an even larger trial. The company reported $431 million for the third quarter and $1.1 billion in sales through Q3. The market is growing 30% this year. AI summary

Investor Event Transcript 2026-11-17 For: 2026-12-31
Added on November 18, 2026

Conference Transcript - MDGL 2026-11-17

Akash Tiwari, Analyst — Jefferies

Good morning, everyone. Day two of our Jeffries Healthcare Conference in London really has been a tremendous success so far, and again, so grateful for the attendance. My name is Akash Tiwari. I lead our pharmaceutical and biotech research efforts internally within the firm, and I have the pleasure of hosting the Madrigal Management Team. Bill, why don't I hand it off to you for some introductory remarks, and we'll get started.

William Sibold, CEO

Great. Well, first of all, thanks for having us here. This is a highlight of the year, one of the highlights of the year for us. So we are off to an objectively outstanding launch after 10 quarters. We recently reported $431 million for the third quarter. You annualized that. That's $1.7 billion run rate, $1.1 billion in sales through Q3. So we've become a blockbuster. in 10 quarters, and we're really just at the very beginning. And remember, the context is for the last five quarters, we've been competing against one of the biggest companies in the world, with one of the largest products of all time, Wagovi, and it hasn't had any impact that we can see. We have a market that is growing 30% this year, which now takes it up to over 530,000 patients. When we first started, we were at 315,000 patients as the potential market. We've built a pipeline in a short period of time, which we think is the industry-leading pipeline, over 55,850 patients on drug. I mean, just as you go metric by metric, we are off to a great start. And maybe the final piece I'll say is that it's still a disease that's only 10% diagnosed and 10% penetrated. So we're at 1% of what we think will be one of the largest specialty markets in the industry. So, firing on all cylinders, great quarter, great prospects ahead.

Akash Tiwari, Analyst — Jefferies

Understood. I'm going to start with not a focus on the quarter, but actually on a board edition that you had. You recently had John Reed, who is sitting R&D head at J&J and on the executive committee there. Join your board. And again, everyone's focused on the launch outcomes, but I feel like that's quite interesting. It's not something we see quite often. Can you talk about what John really brings to the board, how he helps you as you think about stratifying and really owning MASH on a long-term perspective? And again, why him in terms of a board edition?

William Sibold, CEO

Yeah, well, it is very, pardon me, rare to have an acting sitting head of R&D. Fortunately, not conflicted. And I've worked with John in the past, and I think he's just a highest quality character. He has experiences which range from all the way from research through development, but also at senior levels in companies. And, you know, as a CEO and as a leadership team and as a board, what do you want? You want wisdom. You want people that have seen it. They know what good looks like. They know what great looks like. They know what bad looks like. They can help you think through complicated problems and win. John brings that. He is a seasoned executive who, you know, look, I've known him, as I said, for years. I trust John. I think part of the reason John joined is because he sees this as one of those markets where somebody can definitively win. A lot of times... Companies have a successful product. And then they go on to their next indication. Rarely do you have the ability to assemble all the science, and John's a very science-focused guy, where you can assemble all the science and take a leadership role in a space, drive the science, create the science, and benefit from the science. And I think that's what makes us very unique. You know, also, you know, with a big company like J&J, you're conflicted out of a lot of areas that you can work. There aren't so many people still focused on MASH, so that allows them in. But, you know, I like, it's just, it adds a very seasoned... He's an experienced person who can guide us. He also is great from that R2D translational medicine. We have a pipeline that's mostly preclinical, though we have some, you know, phase one, phase two assets as well. So, you know, it's the whole package. We're thrilled to have him. And so far, it's only been one board meeting he's been at, but brought tremendous value.

Akash Tiwari, Analyst — Jefferies

Understood. Now, and again, before we get into the quarter, I remember one of the first times we met, you talked about this dynamic of believers of MASH, or I'll call it NASH, or non-believers, right? And the sense that, well, who knows if this market's actually real? You had this kind of threat of GLP-1s that are going to enter, and what would increments be? And then you also have outcomes, right? And some of these questions are pending. Some of them we might have answers to. So if you were a preacher and you were going to say, I want you to be a believer of Nash, what are the truths, let's say? That you would have to convince people of. And now, you know, 10 plus cores into launch. What do you feel like you've externally shown people on what this opportunity actually is?

William Sibold, CEO

Yeah, look, so we've been fighting a lot of bear theses for a long time. I'm just I've just passed my third year anniversary. And, you know, this was first of all. You heard people talking about this being a big disease, prevalent disease. People are talking about millions and millions of patients. Interesting. More important is it's a serious disease. Number one cause of liver transplants for women in America. Soon to be number one overall. That is a serious disease. I've worked with a lot of serious diseases. Rarely do they have they ended in death or transplant. That's where this disease takes you. I think that there's a little bit of a misunderstanding about that as well, how serious it can be. And I think people are starting to understand that. The question was, is it a market? Are there patients? Well, you know, we didn't subscribe to the theory of, say that there's millions of patients, get 1% market share, it's a blockbuster, invest in us. I don't think that's the right way to do it. I think that's too vague. I don't think that's actionable. I don't think you can create a launch plan around that. That's why we took a very strict interpretation. Who was diagnosed? Who was F2, F3, and who was at the practices that we were calling on, 14,000 prescribers. That's how we got to 315,000 patients. That was through a rigorous using epi, using claims databases, using market research, and using our target list. So we found that there were 315,000 patients. That's where we focused. We created a specialty launch around it. We had done a lot of pharmacoeconomic work, products cost-effective. We could become a specialty launch. And what we've seen is that there are patients that are getting on drug and benefiting to a large degree, 55,850, greater than 55,850. So is there a market? The answer is yes, right? The unmet need and prescribers are willing to prescribe. That's kind of question number one. Is there a future? Yes, market growth is 30% this year, over 30% this year, so that 315 is going to end up likely over 600,000 this year. So there's growth. Do GLP-1s make a difference? Yes, they help with market growth. That is fantastic, right? I think Novo's efforts have helped make awareness greater, especially in the primary care world, and we've benefited from that. However, they haven't had any impact that we can see on our growth, and the reason being is that profiles matter, and how you launch matters. If you look at Wagovi versus ResDifera from a clinical trial perspective, efficacy looks quite similar. In the real world, it's a different story, though, because you have to get to a high enough dose and stay on it long enough, and we know that that's where GLP-1s have their problems. So GLP-1s, that bare thesis, went away. So I think as you look ahead to the future now, it's hard to find a market with the fundamentals as good as this, starting with a high unmet need, significant enough patient population, a profile that looks great with ResDifera. I often call it the Holy Grail profile, a once-a-day pill that's effective, safe, well-tolerated. And now, before anyone else has assembled their pipeline, we have We think, you know, most of the mechanisms, almost all the mechanisms that we would want to put in combination with ResDiffer as a foundational therapy. So, to me, the setup is great, and the fact that we've demonstrated this much progress in 10 quarters, and we're on the runway that we're on, really validates the opportunity, and the numbers that I've given shows a great future.

Akash Tiwari, Analyst — Jefferies

Understood. You know, it's interesting. I feel like if you had said, GLP ones had no impact on our launch 2 years ago. A lot of people would have been very skeptical. I think the empirical data, when we look at your patient ads supports that. You have, um, potentially some other that are entering the market. Um, but you said several times profile. So. I'm going to ask you to call your shot again. So you're having consistent patient ads, 6,000 to 7,000 a quarter. Steadily adding.

William Sibold, CEO

That's the way we refer to it.

Akash Tiwari, Analyst — Jefferies

Right. The adjectives are important here. Do you feel confident that you can have the same steadily adding patient dynamics as we get additional competition towards the end of the decade when you look at the profile of some of your competitors?

William Sibold, CEO

Yeah. I mean, I think that the math just works for one thing is you're going to expand the market so much. There's plenty of patients. There's plenty of patients that still haven't been treated. It's still 90% that qualify by label haven't been treated. These markets just take a long time to develop. That's why when I talk about growth of this market, we see this market growing for decades. That's like every other specialty market. Look at psoriasis after, what, 25 years? Still growing. IBD, same thing. MASH is going to fall into that similar profile where it will just grow for years and years. In that backdrop, through ResDiffer, we see steadily adding patients, continued growth, and then when we bring in the rest of the portfolio, it will open up new opportunities for sub-segments of the market, or hopefully we can make a product that's even more effective.

Akash Tiwari, Analyst — Jefferies

Understood. Now, moving a bit to the outcome studies, and we have three shots on goal here, but I want to address this because, again, I did not expect you to narrow on the ongoing F4 study about when that trial would read out, because it felt like maybe more of a 2027 event, but we also did not expect an announcement of an additional trial. Now, if I am going, like, and you get this question, you're like, oh, man, they announced the timing of the current F4 study, now they're starting another one with more patients. The read is they aren't confident in their current ongoing trial. Now, your team has data that I wish I had, which is your event rate on that trial, but I want you to take that head off, right? Does the move in terms of the new study and the narrowing on timeline exude confidence, or does it suggest that you might be concerned on the powering on the ongoing trial?

William Sibold, CEO

Confidence. First and best. We're not here to participate. We're here to win, right? You need to continuously generate new data in order to continue to extend your leadership position. We want to win F4C. First is going to be Maestro Nash outcomes. We said late 27, Dave can comment a little bit more as we get there, but we also have this opportunity now where we can start an even larger trial that takes in all the learnings from outcomes, plus our open label, plus how the field's moved, so that we can leapfrog the competition that is expected in, I don't know, sometime around 2030 plus. The overall strategy is leadership, winning an F2, F3, F4C. We will continue to generate data across all those patient populations and really carve out this leadership position for ourselves. That's what it's about more than anything. It's looking at that future state of victory. Dave, do you want to comment a little bit?

David Soergel, Other

Yeah, I think the, I guess, two parts to the question. So, Meister outcomes, we've always said that you just need to get farther along in the study and accrue more events to have more confidence in the timing. And, you know, we basically got to that point at the last quarter, so we were able to narrow. Instead of saying, you know, all of 2027's potential, we started saying late 2027. I think the important thing to realize is that it's an outcomes trial, right? So, you know, the events have to accrue for us to stop the study. So if events accelerate, if the event rate accelerates, then we would deliver earlier than late 2027, and if they slow down, it would be a little later. So our best estimate right now, though, is late 2027. With respect to the other study, you know, as Bill said, you know, I think, you know, the opportunity in F4 is large, right? It's a huge unmet medical need, large patient population, a lot of heterogeneity within F4 that we've only been, you know, really started to understand more over the last couple of years. So, you know, Becky and the team did a great job four or five years ago designing a state-of-the-art study for them. But things have moved on. You know, so the field has learned. We've been able to identify the at-risk patient population more effectively using biomarkers and risk scores. You know, there are other sort of regulatory approaches that are starting to become accepted in F4 like varices, for example. So there's a whole range of possibilities, I think, that have emerged over the last few years. In addition to, you know, what we've presented from our open label study, we also have done blinded analyses on Meister outcomes, which gives us even more insight. Now, we're not going to talk specifically about what we've done because, you know, that's data that's in the lockbox right now. But we're able to look at the patient characteristics that predict events, you know, from Meister Outcomes and have even more confidence about how to design the next trial.

Akash Tiwari, Analyst — Jefferies

So but just to be clear, your ongoing study, your level of confidence remains high. Yes. Okay. And just a couple follow ons on that. So one. If you think about, you know, again, your view on event rate progression is different than some of your peers, right? And so you'd have to think that there's also kind of just like non-proportional accumulation of events, right? Now, what I would love to know is what percentage of the total number of events have you had that you can even guide to F4? But you talked about it might go earlier, might go later, but Is it fair to say that the event rate has now picked up, and that would almost make sense with how you've modeled the trial with that time to progression endpoint, and you've reached kind of a period of elevated events, and that's really what gave you confidence in narrowing down the timelines?

David Soergel, Other

I mean, we haven't specifically commented on the trajectory itself. Suffice it to say that we've gotten to a point where we've had enough events accumulate to where we're able to narrow the timing down to the late 2027 timeframe. What I'll say is that, you know, in a trial size of, you know, 845 patients targeting maybe 10% of the type of, you know, the number of events you'd expect for a cardiovascular outcome study, for example, you know, the event accumulation tends to be choppy. You can go weeks without any events, and then you can have three or four events happen in a week. So that choppiness is one of the things that really necessitates you getting far enough along to really be able to predict more precisely the timing of the study. And so what we can say is at this point, we've gotten to an area where we're able to be a bit more precise.

Akash Tiwari, Analyst — Jefferies

Understood. Now, finally, just on the 845, and you mentioned, I think, to Becky's credit, Elf? Platelets. Those are two really bold calls your team made in terms of enrichment that we did not see from other companies in the space. When I talk to you, it doesn't sound like your view on that has actually changed. The where because you alluded to we've learned a little more. Yeah, it seems like the new learnings are one that how much these kind of late stage F3 patients contribute to hepatic events seems like it's de minimis. And then number two is varicose. So 845 patients. Do you feel like your trial is well enriched for the kind of sweet spot target F4 patient? And number two, when you think about your ongoing, your new study. What do you think your sweet spot will be in that population?

David Soergel, Other

Yeah, so I think a couple of things in what you've said. So, yes, Becky did a really good job, VCTE, platelets, MRE, you know, other markers that are, you know, that at that point, four or five years ago, weren't as well established, which what's happened over even the last year is algorithms like anticipate NASH have been, you know, have come out and become more validated. So instead of these sort of categorical ranges of Bivino criteria that were originally used, there was a more sort of disease-specific approach to risk stratification using anticipate NASH that happened last year. So that's evolved. So even the way you combine VCTE and platelets and BMI in the anticipate NASH algorithm helps you understand risk of events within three years. So it's an example of how even though you had the bases four or five years ago, the way you use that information now has gotten more precise. And I mean, you can look at some of the blood-based biomarkers as well. ELF has become more refined. We understand more about risk stratification using ELF. And there are other emerging biomarkers that also look quite promising. Um, so that's, that's really how the field has changed. And so we feel that now to, to, to answer the second part of your question, uh, the outcome study is well enriched, but we can do better, right? So we can do better on the, on the earlier stage patients and really eliminating them from the study because they don't contribute events to your point. But also on the other end of the spectrum, you don't want patients enrolled in an outcome study who the day after you randomize them have an event, right? Right. Because there's no opportunity to intervene with the therapy. And actually change their course. So you need to identify patients who are far enough along, but not too far along. And that's what we call the sweet spot. So I think we can do that better now. We did a good job four or five years ago, but we can do even better now.

Akash Tiwari, Analyst — Jefferies

Understood. I can't help but think, look. Whether, I think we'll eventually get to this point, which is net-net, the new F4 trial is a de-risk, right? In the end of the day. Uh, maybe the first trial is powered appropriately. It sounds like you still feel like that's the case, but this is a backup strategy that allows your company to put itself in a really strong position to de-risk its overall profile. Um, but again, people, you, I know Billy had mentioned this. You can go either way in terms of reading this. What do you think the net takeaway we should be having in terms of the new outcome study?

William Sibold, CEO

Confidence in the brand. I mean, look, we didn't talk about the patient population. When we first reported in 2013, it was 245,000 F4C patients. Now that's gone to 360,000. We've talked about it doubling the opportunity. It's already now bigger than the 315 that we launched. And so, again, it's looking how are you going to be the leader in that space. You've got to continue to generate data. So why not create a study that allows you to have a lot of insight that's not only going to be applicable to ResDiffer, but hopefully to the portfolio beyond that.

Akash Tiwari, Analyst — Jefferies

Understood. Now, maybe towards and the last thing is just on the F2F3 study, which is more of a fixed time point.

David Soergel, Other

Yeah.

Akash Tiwari, Analyst — Jefferies

Now, I don't think investors asked you too much about it, but I. Don't think that means that you're necessarily not confident. But it is this kind of conversion to cirrhosis event, which is different than what we're seeing with the F4 study. So can you educate us investors? For that ongoing F2, F3 study, how is the endpoint different than the F4 ones? And what do you feel like will be the major contributor of events and then kind of your overall level of confidence that that trial will be successful?

David Soergel, Other

Yeah, so we were just talking about the F4 population. You really don't expect decompensation events to happen in patients with the early version of F4. So if you go back even farther to F2, F3, you really don't expect a lot of decompensation events. And so the endpoint is really going to be driven by a histologic measure, which is conversion to cirrhosis at 54 months. So that's a big difference. So we would expect, you know, based on some previous trials, predominantly the Regenerate study, you'd expect somewhere around 90% of your events to be conversion to cirrhosis by biopsy, and maybe a handful of other clinical events in the study.

Akash Tiwari, Analyst — Jefferies

And we finally got the Regenerate data published. But what did that teach your team? Do you feel like that study... The overall outline, the assumptions hold with what you've seen with that data set?

David Soergel, Other

Yeah. So the data have actually been out for a while. They were presented at a conference a while back. So we've had access to the outcomes for a while. It's nice to see them published, of course. So we had already learned when the study was initially designed a couple of important things about the Regenerate population vis-a-vis Maestro Nash. Maestro Nash is actually enriched for risk factors for progression more so than Regenerate was, number one. And number two, Maestro Nash is a longer study. So Regenerate was 48 months and Maestro Nash is 54. So you have a longer time period for the placebo patients to convert to cirrhosis. And there are more risk factors in the overall population for transition to cirrhosis. So we'd expect a higher rate.

Akash Tiwari, Analyst — Jefferies

Last question, Bill, and this will be a general one. But again, your confidence on the safety profile in the real world and your pharmacoviligence team, what you've looked at with ResDifera, how confident are you that, you know, you have a clean drug here? And I'll give you an opportunity to discuss it.

William Sibold, CEO

A thousand percent confident in the efficacy and safety of the product. It's not only gone through a rigorous FDA review, but it also has over 55,000 patients in the real world now. That lets you have a very well-characterized safety and efficacy profile, and everything that we've seen through our rigorous, rigorous pharmacovigilance process suggests the same. The label is reflective of the profile of the product.

Akash Tiwari, Analyst — Jefferies

Understood. With that, I really do thank you. It's a wonderful discussion. Thanks so much, everyone.